|
Mammary Neoplasms
|
0.400 |
AlteredExpression
|
group |
BEFREE |
To get more insight into the role of AR in breast cancer, we additionally performed a retrospective pooled analysis to determine the prognostic value of the AR using mRNA profiles of 7270 primary breast tumors.
|
31077689 |
2019 |
|
Mammary Neoplasms
|
0.400 |
AlteredExpression
|
group |
BEFREE |
Androgen receptor (AR) is expressed in approximately 70% of breast tumors.
|
31126320 |
2019 |
|
Mammary Neoplasms
|
0.400 |
AlteredExpression
|
group |
BEFREE |
Recent advances in the molecular classification of breast tumours have uncovered a subset of breast tumours associated with high expression of androgen receptor mRNA including the so-called 'luminal androgen receptor (LAR) tumours' and 'molecular apocrine tumours' (MATs).
|
30425121 |
2019 |
|
Mammary Neoplasms
|
0.400 |
AlteredExpression
|
group |
BEFREE |
AA breast tumors express AR at lower rates compared to Whites, independent of ER and PR expression (p<0.0001).
|
29912871 |
2018 |
|
Mammary Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
It has also been documented that AR is expressed in more than 60% of breast tumors, which promotes the growth of estrogen receptor-negative (ER<sup>-</sup>)/AR-positive (AR<sup>+</sup>) breast cancer cells.
|
29353883 |
2018 |
|
Mammary Neoplasms
|
0.400 |
AlteredExpression
|
group |
BEFREE |
In addition, C1orf64 closely correlated with AR expression in primary and metastatic breast tumors and C1orf64 expression was relatively higher in breast tumors with a lower grade and lobular histology.
|
28915724 |
2017 |
|
Mammary Neoplasms
|
0.400 |
AlteredExpression
|
group |
BEFREE |
Re-evaluation of the breast tumor immunohistochemistry has shown positive androgen receptor expression and negative expression for estrogen, progesterone and HER-2 receptors.
|
28443693 |
2017 |
|
Mammary Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
A majority (~70%) of breast tumors are found to express estrogen receptor, and a significant portion (~90%) of ER-positive (ER<sup>+</sup>) breast tumors are also androgen receptor-positive (AR<sup>+</sup>).
|
29254284 |
2017 |
|
Mammary Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
Eligible studies were identified by systematic review of electronic databases using the MeSH-terms "breast neoplasm" and "androgen receptor" and were selected after a qualitative assessment based on the REMARK criteria.
|
28151718 |
2017 |
|
Mammary Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
The estrogen receptors (ESRα and β) and the androgen receptor (AR) mediate genomic and non-genomic effects on breast tumor growth and proliferation.
|
25979597 |
2015 |
|
Mammary Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
These findings are in agreement with the hypothesis that AR may stimulate or inhibit breast cancer growth depending on ER status, AR transactivation, and the endocrine-metabolic environment of breast tumors.
|
26541420 |
2015 |
|
Mammary Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
Importantly, we provide ex vivo evidence that AR-V7 is upregulated by the AR antagonist enzalutamide in primary breast tumors.
|
26554309 |
2015 |
|
Mammary Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
Furthermore, gene encoding coagulation factor VII (F7) demonstrated the closest expression pattern with AR (CC=0.716) in the dataset and factor VII protein expression was significantly associated to that of AR in a cohort of 209 breast tumors.
|
25447311 |
2015 |
|
Mammary Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
We found that L1CAM(high)AR(low) primary breast tumors have the worst clinical outcome.
|
25510351 |
2014 |
|
Mammary Neoplasms
|
0.400 |
AlteredExpression
|
group |
BEFREE |
Meta-analysis showed that AR expression in breast tumors was an indicator of better DFS (HR 0.52, 95% CI 0.43-0.64).
|
24324816 |
2013 |
|
Mammary Neoplasms
|
0.400 |
AlteredExpression
|
group |
BEFREE |
Reduced androgen receptor expression accelerates the onset of ERBB2 induced breast tumors in female mice.
|
23593223 |
2013 |
|
Mammary Neoplasms
|
0.400 |
AlteredExpression
|
group |
BEFREE |
We found that PIP is the most regulated molecular apocrine gene by the AR-ERK feedback loop and is overexpressed in ER-/AR+ breast tumors.
|
22817771 |
2012 |
|
Mammary Neoplasms
|
0.400 |
GeneticVariation
|
group |
BEFREE |
In AR negative breast tumours, mutation screening identified the same mutation (T105A) in the 5'UTR of two AR negative breast cancer patients but not reported in the normal human population.
|
22471922 |
2012 |
|
Mammary Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
We find that AR is enriched in ER- breast tumors that overexpress HER2.
|
21741601 |
2011 |
|
Mammary Neoplasms
|
0.400 |
Biomarker
|
group |
CTD_human |
Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies.
|
21633166 |
2011 |
|
Mammary Neoplasms
|
0.400 |
Biomarker
|
group |
CTD_human |
The Possible Impact of Obesity on Androgen, Progesterone and Estrogen Receptors (ERα and ERβ) Gene Expression in Breast Cancer Patients.
|
22174584 |
2011 |
|
Mammary Neoplasms
|
0.400 |
AlteredExpression
|
group |
BEFREE |
Significant differences in AR levels existed among different breast tumor subtypes (highest in estrogen receptor-positive and/or progesterone receptor-positive tumors) as well as by PIK3CA mutation status (P < 0.0001 for both).
|
19276248 |
2009 |
|
Mammary Neoplasms
|
0.400 |
GeneticVariation
|
group |
LHGDN |
Androgen receptor gene CAG repeats, estrogen exposure status, and breast cancer susceptibility.
|
18562955 |
2008 |
|
Mammary Neoplasms
|
0.400 |
Biomarker
|
group |
LHGDN |
Lack of expression of androgen receptor may play a critical role in transformation from in situ to invasive basal subtype of high-grade ductal carcinoma of the breast.
|
18187183 |
2008 |
|
Mammary Neoplasms
|
0.400 |
GeneticVariation
|
group |
LHGDN |
Association of repeat polymorphisms in the estrogen receptors alpha, beta (ESR1, ESR2) and androgen receptor (AR) genes with the occurrence of breast cancer.
|
17904846 |
2008 |